LON:INDV

Indivior Share Forecast, Price & News

GBX 134

+0.80 (+0.60 %)

(As of 04/16/2021 12:00 AM ET)

Add

Compare

Today's Range

132.90

Now: GBX 134▼

135.90

50-Day Range

118.80

MA: GBX 126.71▼

137.60

52-Week Range

44.30

Now: GBX 134▼

165.80

Volume704,099 shs

Average Volume1.34 million shs

Market Capitalization£984.39 million

P/E RatioN/A

Dividend YieldN/A

BetaN/A

Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders. The company's products focuses on treating substance use disorder, opioid use disorder, and schizophrenia. It offers SUBLOCADE injection for subcutaneous use; SUBOXONE sublingual film; and PERSERIS for extended-release injectable suspension, as well as sells legacy analgesic products that include Temgesic, Burpex, and Buprenex. The company is also involved in finance activities. It operates in approximately 40 countries worldwide. Indivior PLC was incorporated in 2014 and is headquartered in North Chesterfield, Virginia.

Industry, Sector and Symbol

Stock Exchange LON

Industry Drugs - Generic

Sub-IndustryN/A

SectorMedical

Current SymbolLON:INDV

Previous Symbol

CUSIPN/A

CIKN/A

Webindivior.com

Phone+44-1753-217800

Employees796

Year FoundedN/A

Debt

Debt-to-Equity Ratio347.56

Current Ratio1.98

Quick Ratio1.74

Price-To-Earnings

Trailing P/E RatioN/A

Forward P/E Ratio26.80

P/E GrowthN/A

Sales & Book Value

Annual Sales£647 million

Price / Sales1.52

Cash FlowGBX 114.02 per share

Price / Cash Flow1.18

Book ValueGBX 11.20 per share

Price / Book11.96

Profitability

EPS (Most Recent Fiscal Year)N/A

Net IncomeN/A

Net MarginsN/A

Return on EquityN/A

Return on AssetsN/A

Miscellaneous

Outstanding Shares734,621,000

Market Cap£984.39 million

Next Earnings DateN/A

OptionableNot Optionable

Headlines

Addex to Present at the 20th Annual Needham Virtual Healthcare Conference - StreetInsider.com
April 13, 2021 | streetinsider.com

Indivior (LON:INDV) Share Price Passes Below 50-Day Moving Average of $127.52
April 2, 2021 | americanbankingnews.com

Indivior revamps board after accord with biggest shareholder Scopia - Morningstar
March 24, 2021 | morningstar.co.uk

Addex Reports Full Year 2020 Financial Results and Provides Corporate Update - StreetInsider.com
March 11, 2021 | streetinsider.com

Addex Therapeutics to Release Full-Year 2020 Financial Results and Host Conference Call on March 11, 2021 - StreetInsider.com
March 9, 2021 | streetinsider.com

Indivior revenue falls as top opioid drug hit by competition, pandemic
February 18, 2021 | nasdaq.com

UPDATE 2-Drugmaker Indivior prepares for pandemic hit to run into 2021
February 18, 2021 | finance.yahoo.com

Drugmaker Indivior warns pandemic pain to extend into 2021
February 18, 2021 | finance.yahoo.com

Reckitt withdraws $1.4 billion claim against Indivior over U.S. opioid probe
January 25, 2021 | finance.yahoo.com

Indivior raises revenue forecast as U.S. opioid treatment sales recover
January 15, 2021 | nasdaq.com

Indivior forecasts revenue above target as opioid treatment sales recover
January 15, 2021 | nasdaq.com

Indivior quarterly profit slumps, sets full-year revenue target - Reuters
October 31, 2020 | reuters.com

UK Stocks-Factors to watch on Oct. 29 - Reuters UK
October 30, 2020 | reuters.com

REFILE-Indivior quarterly profit slumps, sets full-year revenue target | Financial News - London South East
October 29, 2020 | lse.co.uk

Essentra Q3 Revenue Declines By 6.7% On LFL Basis - Quick Facts - Nasdaq
October 23, 2020 | nasdaq.com

Indivior: US Federal Court Sentences Former CEO Shaun Thaxter - Nasdaq
October 23, 2020 | nasdaq.com

MiNA Therapeutics Appoints Peter Bains as Chief Business Officer - StreetInsider.com
September 29, 2020 | streetinsider.com

Indivior targets $70 mln savings through job cuts, restructuring
September 25, 2020 | nasdaq.com

Addex to Present at the Investora Conference - StreetInsider.com
September 23, 2020 | streetinsider.com

Indivior Underscores Commitment to Putting Patients First during this Recovery Month - Yahoo Finance
September 22, 2020 | finance.yahoo.com

See More Headlines

MarketRank^™

Overall MarketRank^™

1.38 out of 5 stars

3.5 Analyst's Opinion

Consensus Rating
Indivior has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of GBX 195, Indivior has a forecasted upside of 45.5% from its current price of GBX 134.
Amount of Analyst Coverage
Indivior has only been the subject of 2 research reports in the past 90 days.

3.4 Community Rank

Outperform Votes
Indivior has received 553 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
Indivior has received 269 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
Indivior has received 67.27% “outperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about Indivior and other stocks. Vote “Outperform” if you believe INDV will outperform the S&P 500 over the long term. Vote “Underperform” if you believe INDV will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
Indivior does not currently pay a dividend.
Dividend Growth
Indivior does not have a long track record of dividend growth.

0.0 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Indivior insiders have not sold or bought any company stock.

0.0 Earnings and Valuation

Price to Earnings Ratio vs. the Market
The P/E ratio of Indivior is -9.09, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Indivior is -9.09, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Indivior has a P/B Ratio of 11.96. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

GBX 134

+0.80 (+0.60 %)

(As of 04/16/2021 12:00 AM ET)

30 days | 90 days | 365 days | Advanced Chart

Receive INDV News and Ratings via Email

Sign-up to receive the latest news and ratings for INDV and its competitors with MarketBeat's FREE daily newsletter.

Indivior (LON:INDV) Frequently Asked Questions

Is Indivior a buy right now?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Indivior in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Indivior stock.
View analyst ratings for Indivior or view top-rated stocks.

What stocks does MarketBeat like better than Indivior?

Wall Street analysts have given Indivior a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Indivior wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

How has Indivior's stock been impacted by COVID-19 (Coronavirus)?

Indivior's stock was trading at GBX 46.21 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, INDV shares have increased by 190.0% and is now trading at GBX 134.
View which stocks have been most impacted by COVID-19.

What price target have analysts set for INDV?

2 Wall Street analysts have issued 1 year target prices for Indivior's stock. Their forecasts range from GBX 185 to GBX 205. On average, they anticipate Indivior's stock price to reach GBX 195 in the next twelve months. This suggests a possible upside of 45.5% from the stock's current price.
View analysts' price targets for Indivior or view top-rated stocks among Wall Street analysts.

Who are Indivior's key executives?

Indivior's management team includes the following people:

Mr. Mark Crossley, CEO & Exec. Director
Mr. Ryan Preblick, CFO & Exec. Director
Dr. Christian Heidbreder, Chief Scientific Officer
Mr. Jason Thompson, VP of Investor Relations
Ms. Cynthia Cetani, Chief Integrity & Compliance Officer
Mr. Jon Fogle, Chief HR Officer
Mr. Richard Simkin, Chief Commercial & Strategy Officer
Ms. Sue Learned, Sr. VP of Global Clinical Devel.
Hillel West, Chief Manufacturing & Supply Officer
Ms. Kathryn Hudson, Company Sec.

Who are some of Indivior's key competitors?

Some companies that are related to Indivior include SmileDirectClub (SDC), Glaukos (GKOS), National Vision (EYE), CareDx (CDNA), Agios Pharmaceuticals (AGIO), Ablynx (ABLYF), CONMED (CNMD), Cronos Group (CRON), Atea Pharmaceuticals (AVIR), Cantel Medical (CMD), Apellis Pharmaceuticals (APLS), AMN Healthcare Services (AMN), Clover Health Investments (CLOV), Turning Point Therapeutics (TPTX) and NuVasive (NUVA).
View all of INDV's competitors.

What other stocks do shareholders of Indivior own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Indivior investors own include Bigblu Broadband (BBB), Futura Medical (FUM), Directa Plus (DCTA), Lakehouse (LAKE), Aquila Services Group (AQSG), Benchmark (BMK), Bodycote (BOY), (CITY.L) (CITY), Deltex Medical Group (DEMG) and Kingfisher (KGF).

What is Indivior's stock symbol?

Indivior trades on the London Stock Exchange (LON) under the ticker symbol "INDV."

How do I buy shares of Indivior?

Shares of INDV and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
Compare Top Brokerages Here.

What is Indivior's stock price today?

One share of INDV stock can currently be purchased for approximately GBX 134.

How much money does Indivior make?

Indivior has a market capitalization of £984.39 million and generates £647 million in revenue each year.

How many employees does Indivior have?

Indivior employs 796 workers across the globe.

What is Indivior's official website?

The official website for Indivior is indivior.com.

Where are Indivior's headquarters?

Indivior is headquartered at 103-105 Bath Road, SLOUGH, SL1 3UH, United Kingdom.

How can I contact Indivior?

Indivior's mailing address is 103-105 Bath Road, SLOUGH, SL1 3UH, United Kingdom. The specialty pharmaceutical company can be reached via phone at +44-1753-217800.

This page was last updated on 4/16/2021 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here